Cargando…

Correction to: In vitro activity of sulopenem and comparator agents against Enterobacterales and anaerobic clinical isolates collected during the SENTRY Antimicrobial Surveillance Program

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232260/ https://www.ncbi.nlm.nih.gov/pubmed/37130004 http://dx.doi.org/10.1093/jac/dkad140

Ejemplares similares

In vitro activity of sulopenem and comparator agents against Enterobacterales and anaerobic clinical isolates collected during the SENTRY Antimicrobial Surveillance Program
por: Maher, Joshua M, et al.
Publicado: (2023)

In Vitro Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program
por: Shortridge, Dee, et al.
Publicado: (2022)

2761. Activity of Cefiderocol and Comparator Agents Against Achromobacter and Burkholderia Isolates, Collected During 2020-2022 as Part of SENTRY Antimicrobial Surveillance Program
por: DeJonge, Boudewijn L, et al.
Publicado: (2023)

Sulopenem Disk Development, Quality Control Range, and MIC to Disk Result Correlation for Enterobacterales Isolates
por: Puttagunta, Sailaja, et al.
Publicado: (2023)

The Importance of Antimicrobial Resistance Monitoring Worldwide and the Origins of SENTRY Antimicrobial Surveillance Program
por: Fuhrmeister, Andrew S, et al.
Publicado: (2019)

2762. Activity of Cefiderocol and Comparator Agents Against Difficult to Treat Resistance (DTR) Gram-negative Isolates, Collected During 2020-2022 as Part of SENTRY Antimicrobial Surveillance Program
por: DeJonge, Boudewijn L, et al.
Publicado: (2023)

The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program
por: Diekema, Daniel J., et al.
Publicado: (2019)

Twenty-Year Trends in Antimicrobial Susceptibilities Among Staphylococcus aureus From the SENTRY Antimicrobial Surveillance Program
por: Diekema, Daniel J, et al.
Publicado: (2019)

2790. Activity of Cefiderocol and Comparator Agents Against Pediatric Isolates of Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia from the SENTRY Surveillance Program (2020-2022)
por: Nguyen, Sean T, et al.
Publicado: (2023)

Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program
por: Pfaller, Michael A., et al.
Publicado: (2018)

Correction: Antifungal susceptibilities of opportunistic filamentous fungal pathogens from the Asia and Western Pacific Region: data from the SENTRY Antifungal Surveillance Program (2011–2019)
por: Pfaller, Michael A., et al.
Publicado: (2021)

Variations in the Occurrence of Resistance Phenotypes and Carbapenemase Genes Among Enterobacteriaceae Isolates in 20 Years of the SENTRY Antimicrobial Surveillance Program
por: Castanheira, Mariana, et al.
Publicado: (2019)

Correction to: Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial
Publicado: (2023)

Antimicrobial Susceptibility of Acinetobacter calcoaceticus–Acinetobacter baumannii Complex and Stenotrophomonas maltophilia Clinical Isolates: Results From the SENTRY Antimicrobial Surveillance Program (1997–2016)
por: Gales, Ana C, et al.
Publicado: (2019)

Temporal and Geographic Variation in Antimicrobial Susceptibility and Resistance Patterns of Enterococci: Results From the SENTRY Antimicrobial Surveillance Program, 1997–2016
por: Pfaller, Michael A, et al.
Publicado: (2019)

Geographic and Temporal Patterns of Antimicrobial Resistance in Pseudomonas aeruginosa Over 20 Years From the SENTRY Antimicrobial Surveillance Program, 1997–2016
por: Shortridge, Dee, et al.
Publicado: (2019)

37. Bloodstream Infections in the United States and Europe: Etiology and Antimicrobial Susceptibility Results from the SENTRY Antimicrobial Surveillance Program (2016–2019)
por: Sader, Helio S, et al.
Publicado: (2020)

2043. In Vitro Activity of Manogepix Against 2,810 Fungal Isolates from the SENTRY Surveillance Program (2020-2021) Stratified by Infection Type
por: Huband, Michael D, et al.
Publicado: (2022)

In Vitro Susceptibility to Ceftazidime-Avibactam and Comparator Antimicrobial Agents of Carbapenem-Resistant Enterobacterales Isolates
por: Lim, Tze-Peng, et al.
Publicado: (2023)

1572. Combination Cefuroxime and Sulopenem is active in vitro against Mycobacterium abscessus
por: Dousa, Khalid M, et al.
Publicado: (2020)

SENTRY Program Participating Sites (1997–2016)
Publicado: (2019)

In Vitro Evaluation of Delafloxacin Activity when Tested Against Contemporary community-Acquired Bacterial Respiratory Tract Infection Isolates (2014–2016): Results from the Sentry Antimicrobial Surveillance Program
por: Shortridge, Dee, et al.
Publicado: (2017)

2176. In Vitro Evaluation of Delafloxacin Activity Against Contemporary US Isolates from Cystic Fibrosis Patients Hospitalized with Pneumonia: Results from the SENTRY Antimicrobial Surveillance Program (2019-2021)
por: Shortridge, Dee, et al.
Publicado: (2022)

Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program
por: Pfaller, Michael A., et al.
Publicado: (2017)

Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997–2016
por: Pfaller, Michael A, et al.
Publicado: (2019)

Effects of breakpoint changes on carbapenem susceptibility rates of Enterobacteriaceae: Results from the SENTRY Antimicrobial Surveillance Program, United States, 2008 to 2012
por: Rennie, Robert P, et al.
Publicado: (2014)

1734. Susceptibility of Cefiderocol between US Census Regions against Gram-Negative Organisms collected from the SENTRY Surveillance Program: 2020-2021
por: Kung, Frank H, et al.
Publicado: (2022)

1567. In Vitro Activity of Aztreonam-Avibactam and Comparator Agents Against Multidrug-Resistant Enterobacterales Collected Globally as Part of the ATLAS Surveillance Program, 2016-2018
por: Kazmierczak, Krystyna, et al.
Publicado: (2020)

2128. In Vitro Activity of Ceftibuten-Avibactam and Comparator Agents Against Resistant Enterobacterales from UTIs Collected Globally as Part of the ATLAS Surveillance Program, 2022
por: Hackel, Meredith, et al.
Publicado: (2023)

2791. Antimicrobial Activity of Cefiderocol and Comparator Agents Against Isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia by Infection Type from United States Hospitals in the SENTRY Antimicrobial Surveillance Program (2020-2022)
por: Nguyen, Sean T, et al.
Publicado: (2023)

Epidemiology and in vitro activity of ceftazidime-avibactam and comparator agents against multidrug-resistant isolates of Enterobacterales and Pseudomonas aeruginosa collected in Latin America as part of the ATLAS surveillance program in 2015‒2020
por: Wise, Mark G., et al.
Publicado: (2023)

1715. In Vitro Antibacterial Activity of Cefiderocol against Difficult-to-treat Resistant (DTR) Gram-negative Pathogens in United States from SENTRY Antimicrobial Surveillance Program in 2020/2021
por: Yamano, Yoshinori, et al.
Publicado: (2022)

Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from respiratory samples of patients hospitalized with pneumonia in Western Europe, Eastern Europe and the USA: results from the SENTRY Antimicrobial Surveillance Program (2016–19)
por: Sader, Helio S, et al.
Publicado: (2021)

In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017–2019
por: Karlowsky, James A., et al.
Publicado: (2021)

155. In Vitro Evaluation of Delafloxacin Activity Against Contemporary US Isolates from Community-Acquired Pneumonia and Community-Acquired Lower Respiratory Tract Infections: Results from the SENTRY Antimicrobial Surveillance Program (2014-2020)
por: Shortridge, Dee, et al.
Publicado: (2021)

1724. Murine Efficacy Studies of Sulopenem Against Bacillus anthracis
por: Puttagunta, Sailaja, et al.
Publicado: (2022)

2568. Characterization of Sulopenem Pharmacokinetics-Pharmacodynamics Using a One-Compartment In Vitro Infection Model
por: VanScoy, Brian D, et al.
Publicado: (2023)

1252. In Vitro Activity of Aztreonam-Avibactam and Comparator Agents Against Enterobacterales from Patients with Bloodstream Infections collected during the ATLAS Global Surveillance Program, 2015-2019
por: Lob, Sibylle, et al.
Publicado: (2021)

1717. In Vitro Activity of Aztreonam-Avibactam Against Enterobacterales Isolated from Pediatric and Adult Patients Collected During the ATLAS Global Surveillance Program, 2017-2020
por: Estabrook, Mark, et al.
Publicado: (2022)

2119. In Vitro Activity of Aztreonam-Avibactam Against Enterobacterales Isolated from Pediatric and Adult Patients Collected During the ATLAS Global Surveillance Program, 2017-2021
por: Estabrook, Mark, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3qrehjic9gh80kpalfdq9akg91